Saturday 17 October 2026
Export ANTX’s income statement to Excel — free account
AN2 Therapeutics, Inc.
ANTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 14.3% and free cash flow grew 7.91%, each against the same quarter a year earlier. Dividend growth for three consecutive years; insiders bought in the last twelve months.
3.38
0.22
−6.11%
Follow ANTX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
6.87 | 8.43 | 7.87 | 13.72 | 17.70 | 2.90 | 35.85 | — |
Net Debt/EBITDA |
1.48 | 1.39 | 1.48 | 2.24 | 2.72 | 0.56 | 1.08 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.85 | 0.96 | 0.82 | 0.78 | 0.73 | 0.37 | 0.43 | — |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| (52.14%) | (49.69%) | (58.83%) | (178.38%) | 82.85% | 111.67% | 43.91% | — | |
| (45.67%) | (44.47%) | (53.65%) | (50.96%) | (80.68%) | (293.62%) | (201.19%) | — | |
ROIC |
0.00% | 0.00% | (250.04%) | 0.00% | (402.14%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(68.68%) | (67.51%) | (67.10%) | (46.78%) | (49.48%) | (525.55%) | (103.48%) | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(0.99) | (1.65) | (2.26) | (2.18) | (7.76) | (2.09) | (0.13) | — |
Cash per Share |
1.92 | 2.80 | 4.55 | 6.26 | 22.20 | 1.58 | 0.30 | — |
Shareholders Equity per Share |
1.76 | 2.74 | 5.28 | 6.22 | 23.47 | 1.07 | 0.26 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.76 | 2.74 | 5.28 | 6.22 | 23.47 | 1.07 | 0.26 | — |
Free Cash Flow |
(29.83) | (49.26) | (53.29) | (33.46) | (20.48) | (5.36) | (2.49) | — |
Working Capital |
51.22 | 76.02 | 96.46 | 91.44 | 56.71 | 2.78 | 5.54 | — |
Net Current Asset Value |
51.05 | 76.02 | 96.46 | 91.43 | 56.70 | 2.75 | 4.81 | — |
| Other line items | ||||||||
Quick Ratio |
6.65 | 8.17 | 7.64 | 13.37 | 17.25 | 2.79 | 35.21 | — |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Cash ROIC |
(26.86%) | (29.77%) | (22.97%) | (17.48%) | (17.00%) | (78.64%) | (23.88%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Inventory Turnover |
— | — | — | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Days of Inventory on Hand |
— | — | — | 0.00 | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.99) | (1.65) | (2.26) | (2.18) | (7.76) | (2.09) | (0.13) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
3.17 | 3.00 | 2.40 | 1.59 | 0.60 | — | — | — |
Average Assets |
77.02 | 115.42 | 120.65 | 83.94 | 34.78 | 4.97 | 2.85 | — |
Average Common Equity |
67.45 | 103.28 | 110.04 | 23.98 | (33.86) | (13.06) | (13.06) | — |
Columns are period end dates